418 related articles for article (PubMed ID: 28922964)
1. Oral treprostinil in the treatment of pulmonary arterial hypertension.
Feldman J; Habib N; Radosevich J; Dutt M
Expert Opin Pharmacother; 2017 Oct; 18(15):1661-1667. PubMed ID: 28922964
[TBL] [Abstract][Full Text] [Related]
2. Different efficacy of inhaled and oral medications in pulmonary hypertension.
AbuHalimeh BJ; Parambil JG; Tonelli AR
Heart Lung; 2017; 46(4):334-337. PubMed ID: 28527831
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic evaluation of treprostinil (oral) for the treatment of pulmonary arterial hypertension.
Hellawell JL; Bhattacharya S; Farber HW
Expert Opin Drug Metab Toxicol; 2014 Oct; 10(10):1445-53. PubMed ID: 25204984
[TBL] [Abstract][Full Text] [Related]
4. Oral treprostinil diethanolamine for pulmonary arterial hypertension.
Feldman J; Im Y; Gill K
Expert Rev Clin Pharmacol; 2015 Jan; 8(1):55-60. PubMed ID: 25409915
[TBL] [Abstract][Full Text] [Related]
5. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial.
Tapson VF; Torres F; Kermeen F; Keogh AM; Allen RP; Frantz RP; Badesch DB; Frost AE; Shapiro SM; Laliberte K; Sigman J; Arneson C; Galiè N
Chest; 2012 Dec; 142(6):1383-1390. PubMed ID: 22628490
[TBL] [Abstract][Full Text] [Related]
6. Transition from treprostinil to selexipag in patients with pulmonary arterial hypertension: Case series.
Fanous SM; Janmohamed M
Am J Health Syst Pharm; 2018 Dec; 75(23):1877-1881. PubMed ID: 30301721
[TBL] [Abstract][Full Text] [Related]
7. Selexipag: First Global Approval.
Scott LJ
Drugs; 2016 Mar; 76(3):413-8. PubMed ID: 26846322
[TBL] [Abstract][Full Text] [Related]
8. Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study.
Frost A; Janmohamed M; Fritz JS; McConnell JW; Poch D; Fortin TA; Miller CE; Chin KM; Fisher M; Eggert M; McEvoy C; Benza RL; Farber HW; Kim NH; Pfister T; Shiraga Y; McLaughlin V
J Heart Lung Transplant; 2019 Jan; 38(1):43-50. PubMed ID: 30391194
[TBL] [Abstract][Full Text] [Related]
9. What Is the Role of Oral Prostacyclin Pathway Medications in Pulmonary Arterial Hypertension Management?
El Yafawi R; Wirth JA
Curr Hypertens Rep; 2017 Oct; 19(12):97. PubMed ID: 29071454
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial.
Jing ZC; Parikh K; Pulido T; Jerjes-Sanchez C; White RJ; Allen R; Torbicki A; Xu KF; Yehle D; Laliberte K; Arneson C; Rubin LJ
Circulation; 2013 Feb; 127(5):624-33. PubMed ID: 23307827
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension.
Keogh AM; Jabbour A; Weintraub R; Brown K; Hayward CS; Macdonald PS
J Heart Lung Transplant; 2007 Nov; 26(11):1079-83. PubMed ID: 18022071
[TBL] [Abstract][Full Text] [Related]
12. Transition of Intravenous Treprostinil to Oral Therapy in a Patient with Functional Class IV Chronic Thromboembolic Pulmonary Hypertension.
Thurber KM; Williams BM; Bates RE; Frantz RP
Pharmacotherapy; 2017 Aug; 37(8):e76-e81. PubMed ID: 28513869
[TBL] [Abstract][Full Text] [Related]
13. Successful transition from Treprostinil to Selexipag in patient with severe pulmonary arterial hypertension.
Furukawa A; Tamura Y; Iwahori H; Goto M; Ohashi N; Okabe T; Kawamura A
BMC Pulm Med; 2017 Oct; 17(1):135. PubMed ID: 29073911
[TBL] [Abstract][Full Text] [Related]
14. Treprostinil for the treatment of pulmonary arterial hypertension.
Torres F; Rubin LJ
Expert Rev Cardiovasc Ther; 2013 Jan; 11(1):13-25. PubMed ID: 23259441
[TBL] [Abstract][Full Text] [Related]
15. Selexipag for the treatment of pulmonary arterial hypertension.
Richter MJ; Gall H; Grimminger J; Grimminger F; Ghofrani HA
Expert Opin Pharmacother; 2016 Sep; 17(13):1825-34. PubMed ID: 27467883
[TBL] [Abstract][Full Text] [Related]
16. Rapid transition from oral selexipag to parenteral treprostinil in a patient with mixed-etiology pulmonary hypertension.
Radosevich JJ; DeChristopher A; Irandost M; Fann J; Feldman J
Am J Health Syst Pharm; 2020 Jul; 77(15):1208-1212. PubMed ID: 32620953
[TBL] [Abstract][Full Text] [Related]
17. Single-Center Experience Using Selexipag in a Pediatric Population.
Gallotti R; Drogalis-Kim DE; Satou G; Alejos J
Pediatr Cardiol; 2017 Oct; 38(7):1405-1409. PubMed ID: 28702718
[TBL] [Abstract][Full Text] [Related]
18. Inhaled treprostinil: a therapeutic review.
Channick RN; Voswinckel R; Rubin LJ
Drug Des Devel Ther; 2012; 6():19-28. PubMed ID: 22291467
[TBL] [Abstract][Full Text] [Related]
19. Oral treprostinil for the treatment of pulmonary arterial hypertension.
de Lartigue J
Drugs Today (Barc); 2014 Aug; 50(8):557-65. PubMed ID: 25187906
[TBL] [Abstract][Full Text] [Related]
20. A Special Focus on Selexipag - Treatment of Pulmonary Arterial Hypertension.
Sorensen LM; Wehland M; Kruger M; Simonsen U; Nassef MZ; Infanger M; Grimm D
Curr Pharm Des; 2017; 23(34):5191-5199. PubMed ID: 28891448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]